The hypotensive effect of d-tubocurarine 0·5 mg/kg, with and without benzyl alcohol and sodium metabisulphite as preservatives, was studied in 38 pairs of subjects in a double blind, controlled, sequential trial. It is concluded that the preservatives do not significantly contribute to the hypotension produced by d-tubocurarine in clinical practice.
INTRODUCTION
In-vitro studies by Carrier and Murphy (1970) and Dowdy et al. (1971) demonstrated that the negative inotropic effect of d-tubocurarine previously reported (Dowdy et al. 1965 ) was due to the preservatives used in commercial preparations of the drug rather than a direct effect of the drug itself.
A double blind trial was undertaken in an attempt to discover the clinical significance of any contribution played by preservatives to the arterial hypotension commonly observed following the administration of d-tubocurarine. A comparison was made of the effects on the blood pressure of d-tubocurarine, with and without preservative, during clinical anaesthesia. In order to obtain a statistically valid answer with the smallest number of trials, a sequential design was adopted.
MATERIAL AND METHODS
Patients over the age of 18 years requiring endotracheal intubation and profound muscle relaxation for routine surgery were considered for inclusion in the trial. Excluded from the trial were patients undergoing emergency surgery, those with known disturbances of water or electrolyte balance, and those with known or anticipated abnormal responses to allY of the agents to be used.
d-Tubocurarine, 10 mg/ml, was made available in 1·5 ml ampoules labelled A or B. One of these preparations contained benzyl alcohol 1·5 per cent as bacteriostatic preservative, and sodium metabisulphite 0·14 per cent as antioxidant, while the other preparation was a plain aqueous solution. It was not known by any of those participating in the trial which of the preparations (A or B) contained the preservatives.
The patients were premedicated with papaveretum 10-20 mg and hyoscine hydrobromide 0 ,2-0,4 mg, intramuscularly 45-90 minutes before anaesthesia.
Induction of anaesthesia was performed with 2·5 per cent thiopentone given slowly to the point of jaw relaxation. This was followed by suxamethonium 1 mg/kg, and after ventilation with oxygen an endotracheal tube was passed. Controlled ventilation was continued with nitrous oxide-oxygen mixture (4: 21/min). When some return of neuromuscular conduction was noted, d-tubocurarine 0·5 mg/kg was injected over 15 seconds. All drugs were administered into the tubing of a freely dripping intravenous infusion of Hartmann's solution.
Systolic and diastolic blood pressures were measured with a brachial sphygmomanometer cuff and stethoscope. The pulse rate was counted simultaneously by palpation at another site. Observations were made before inductioll, after administration of thiopentone and suxamethonium, and at one-minute intervals after intubation until d-tubocurarine was given. After the injection of d-tubocurarine readings were taken at thirty-second intervals for five minutes and then at seven, nine and eleven minutes. Positioning and preparation for surgery was delayed until completion of the study.
In the initial:20 studieO', subjects wcrc allocated at random to groups A and B. (Group A received drug A, group B received drug B).
\\"hen these initial studie:-; were completed, " matching" was begun, and subjects, one from cach group, "'ere paired for sex and age (±five years). Patients available for study were giYen the appropriate drug if they could complete a pair; if not, they were given A or B at random, and placed on the list of unmatched subjects.
\\"hen a pair of subjects were lllatdled, the lowest mean arterial pressure (diastolic pressure + A pulse prcssure) after the administration of d-tubocurarine was calculated for each paticnt. Thi:-; pressure ,\"as cxpresscd as a percentage of the subject's mean arterial pressure at the commencement of the study (prior to thiopentone and suxanwthonium) and also as a percE'ntage of the last pressure recorded 20 20 FIGURE I.-The sequential analysis chart of the trial. The unbroken line represents the results using the pre-induction mean arteria) pressure as control.
The broken line usccl the last reading before injection of cl-tubocurarine as control. ,\ .. step" upwards represents greater fall in mean arterial pressure in the subject recci"ing drug .\; a stcp down when the subject giycn drug II expnienced the greater fall.
before d-tubocurarine was given. In any matched pair, if a fall in pressure in the subject given drug A exceeded that in the subject given drug B a preference for A was E'ntE'red on the sequential chart. If B exceeded A, a preferE'nce for B was recorded.
It is disputable which of the two readings llsed as control (the rE'ading before thiopentone or thc last rcading before d-tubocurarine) was more appropriate. Both results were therefore charted and the trial was continued until both lines crossed a boundary on the sequential chart ( Figure 1) .
The sequential design adopted (Armitage 191iO) assumes a probability of a difference between A and B of 0 ·S. The leyel of the test (probability of rejecting a true difference) is O' Oil and the power (probability of detecting a true difference) is 0 ·95. This dcsign reaches a conclusion in 40, or less, paired trials.
In order to follow the sequence of changes in blood pressure and pulse rates during the studies the mean of each reading was determined for each group and standard error was calculated.
The" t " test was USE'ci to compare the means.
At the conclusion of the study the drug co(ie was broken, which showed that drug A had contained the preservatives while drug B was the plain aqueous solution.
REO'ULTS \\"Iwn the sequential chart indicated that the stud,· had reached a conclusion using both " controls ", the mean age, weight, close of tiliopentone and dose of suxamethonium were calculated for each group. These were fOllnd to he without significant difference, and are shown in Table 1 . Using the pre-thiopentone blood pressurE' measurement as control, the sequential chart ( Figure 1 ) demonstrated a "not different" result between drugs A and B at the t"'entysixth trial. However, when the last reading before d-tubocurarine was used as the control it took 38 trials before the O'amc conclusioll was reached. The sequence of changes in blood pressure and pulse rate is shown in Table 2 and Figure 2 . No statistically significant differences emerged between the two groups when the corresponding mean pressures were compared.
Similarly, comparison of the lowest recorded mean pressures after d-tubocurarine (at 3t minutes for group A and 4t minutes for group B) failed to show significant difference. However, these lowest pressures (both systolic and diastolic) were significantly different (p < 0 ·001) from those recorded prior to induction and those taken three minutes after intubation.
The average of the maximum falls in systolic blood pressure was 23 per cent in group A and 21 per cent in group B. For diastolic pressure the figures were 17 and 15 per cent respectively. The frequency distribution of the maximum change in mean arterial pressure after d-tubocurarine is shown in Table 3 . DISCUSSION Hypotension after intravenous d-tubocurarine has been recognized for many years (Cullen 1943) . Various explanations have been given, Anaesthesia and hltensive Care, Vol. I, No. 4, .Hay, 197.3 Stoelting (19i I) compared the effect in man of the preservati"e containing diluent with cl-tubocurarine in the same solution. He demonstrated Cl significant fall in mean arterial pressure following d-tubocurarine, but the slight fall which followed the diluent proved statistically not significant.
The study did not exclude a significant contribution by preservatives to the d-tubocurarine-induced fall 111 pressure. The present study compares the hypotensive effect of d-tubocurarine alone with that of cl-tubocurarine plus preservatives. The results demonstrate no significant difference and it can be concludecl that the preservatives (benz~'1 alcohol 1·5 per cent and sodium metabisulphite O' J -! per cent) do not contribute significanth' to the hypotension produced by cl-tubo-curarIne 0·5 mg/kg. ACK;\OW] .EDGE:\IEXTS \Ye are grateful to Burroughs \\-ellcome (Australia) Pty. Ltd. for supplies of cl-tubocurarine with and without preservatives. \\"e are indebted to O1'r surgical colleagues whose helpful patience made this trial possible. 
